Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | CHRND | Q07001 | 1/20 | 0.45 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21074660 | 0.91 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL21074782 | 0.77 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL21074733 | 0.76 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL21074715 | 0.75 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL29761231 | 0.72 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL6886940 | 0.72 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL719753 | 0.71 | HTR2C (0.42) | CHRNB2CHRNA4PDGFRBPDGFRACHRNB4 | |
| SCHEMBL14437924 | 0.70 | PDGFRB (0.63) | PDGFRBPDGFRA | |
| SCHEMBL14117078 | 0.68 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL13285194 | 0.68 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | GRIK4, GRIK2, GRIK5 | CHRNB2 83/4885CHRNA4 64/4885PDGFRB 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.